Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

From what we can see, insiders were net sellers in Johnson & Johnson's ( NYSE:JNJ ) during the past 12 months. That ...

Lazari Capital Management Inc. raised its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC.

After the microchip company SaveThisLife closed its doors, many pet owners say they're double checking where the chip was registered.

Johnson & Johnson's financial results are generally steady and consistent. Check out the chart of revenue and net income below. The company's balance sheet is rock solid and has earned it an AAA ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. If investing in a company came down to size, the stock would be a no-brainer buy. However ...